Amend CSSB 1566 as follows:                                                  
	On page 2, strike lines 22 through 24 and replace it with the 
following:     
		(2)  legislative or administrative changes to policies 
and programs that affect product specific reimbursement to 
providers, including new payment for anti-hemophilia factor 
including various reimbursement methodologies for anti-hemophilic 
factors in the Medicaid program that provide access to appropriate 
treatment.